2-Amino-3-methyl-1-thiazolidin-3-yl-pentan-1-one

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Amino-3-methyl-1-thiazolidin-3-yl-pentan-1-one
• 英文别名: 2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one
• 化学式: C₉H₁₈N₂OS
• 分子量: 202.32
• InChiKey: WCRLBFHWFPELKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
  申请人：Novartis AG

  公开号：EP1741447A2

  公开（公告）日：2007-01-10

  The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phopshate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase - IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis;and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.

  本发明涉及一种组合物，该组合物包括 DPP-IV 抑制剂和至少一种其他抗糖尿病化合物，这些化合物最好选自胰岛素信号通路调节剂（如蛋白酪氨酸磷酸酶（PTPases）抑制剂）、非小分子模拟化合物和谷氨酰胺-果糖-6-槐糖酸酰胺基转移酶（GFAT）抑制剂、影响肝脏葡萄糖失调的化合物、非小分子模拟化合物和谷氨酰胺-果糖-6-卟吩氨酸脒基转移酶（GFAT）抑制剂，影响肝糖生成失调的化合物，如葡萄糖-6-磷酸酶（G6Pase）抑制剂、果糖-1,6-二磷酸酶（F-1,6-BPase）抑制剂、糖原磷酸化酶（GP）抑制剂、胰高血糖素受体拮抗剂和磷酸烯醇丙酮酸羧激酶（PEPCK）抑制剂、丙酮酸脱氢酶激酶（PDHK）抑制剂、胰岛素敏感性增强剂、胰岛素分泌增强剂、α-葡萄糖苷酶抑制剂、胃排空抑制剂、胰岛素和α2-肾上腺素能拮抗剂，可同时、单独或依次用于预防、延缓或治疗各种疾病的进展、二肽基肽酶 IV（DPP-IV）介导的疾病，特别是糖尿病，尤其是 2 型糖尿病、糖耐量受损（IGT）、空腹血浆葡萄糖受损、代谢性酸中毒、酮病、关节炎、肥胖症和骨质疏松症的预防、延缓恶化或治疗；将这种组合用于哺乳动物的美容治疗，以达到减肥的美容效果。
• Adamantylglycine derivatives as inhibitors of dipeptidyl peptidase IV for the treatment of diabetes
  申请人：Bristol-Myers Squibb Company

  公开号：EP1997489A1

  公开（公告）日：2008-12-03

  The compounds of the present invention are adamantylglycine-based inhibitors of dipeptidyl peptidase IV (DPP-IV) and are useful for the treatment of diabetes and related diseases.

  本发明的化合物是基于金刚烷基甘氨酸的二肽基肽酶 IV（DPP-IV）抑制剂，可用于治疗糖尿病及相关疾病。
• COMBINATIONS COMPRISING AN ANTIDIARRHEAL AGENT AND AN EPOTHILONE OR AN EPOTHILONE DERIVATIVE
  申请人：NOVARTIS AG

  公开号：EP1372650B1

  公开（公告）日：2008-11-19
• ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES
  申请人：Bristol-Myers Squibb Company

  公开号：EP1658066B1

  公开（公告）日：2009-09-30
• SUBSTITUTED XANTHINE DERIVATIVES
  申请人：Concert Pharmaceuticals Inc.

  公开号：EP3199203B1

  公开（公告）日：2020-02-05